Los metales tóxicos normalmente están presentes en cantidades muy pequeñas en nuestro organismo, pero la exposición continua a ellos o las anormalidades en el mecanismo de eliminación del exceso de estos metales pueden provocar problemas muy serios y, en ocasiones, con síntomas difíciles de diagnosticar. Por ejemplo:
EDTA: Ethylene Diamine Tetra Acetic Acid - A Review by E. Blaurock-Busch, published in Occupational Medicine & Health Affairs 2016 4:4
Chelation therapists around the world incorporate EDTA treatments in their daily practice, often unaware of the chemical differences of the various chelating agents. Misunderstandings increase the risk of iatrogenic accidents. This information aims to prevent this.
Original Research Paper publ Jan 2014, British Journal of Medicine and Medical Research:
Comparison of Chelating Agents DMPS, DMSA and EDTA for the Diagnosis and Treatment of Chronic Metal Exposure
The chelating agents most commonly used to treat chronic metal overexposures are DMSA, DMPS and EDTA. We evaluated and compared the effectiveness of each of those chelating agents and statistically determined what metals are best bound. Based on the metal binding capacity and practicality of use, we determined that intravenously applied DMPS is best used as a provocation or mobilization test.
At present, it is assumed that the application of higher amounts of a chelating agent increases metal binding and thus the detoxification process. This does not seem to be the case. The manufacturer of DMPS (Dimaval), Heyl Berlin published data that indicate that for instance 2 or more ampules of DMPS intravenously applied do not result in double binding.
The same principle applies to other chelating agents. For example, when comparing 500mg to 1000mg DMSA applied orally, results do not increase as expected.
Study data and statistics are included.
Full article (in German only):
Chelation therapy is used for the treatment of chronic metal overexposures of varying degrees and appropriate diagnostics allow proper and safe treatment. The use of diagnostics aids the physician in setting therapy schedules, allows proper selection of the most useful chelating agent for the patient's condition, and monitors treatment success.
For detailed information, see our books.
The randomized, double-blind trial of NaMgEDTA Chelation provided surprising benefits for patients who had suffered at least one Myocardia Infarct (MI) and was particularly beneficial to increase circulation in diabetics, Dr. Gervasio Lamas of the Mount Sinai Medical Center, Miami Beach, Fl. stated.